HK1112718A1 - Aqueous ophthalmic suspension of crystalline rebamipide - Google Patents

Aqueous ophthalmic suspension of crystalline rebamipide

Info

Publication number
HK1112718A1
HK1112718A1 HK08101628.0A HK08101628A HK1112718A1 HK 1112718 A1 HK1112718 A1 HK 1112718A1 HK 08101628 A HK08101628 A HK 08101628A HK 1112718 A1 HK1112718 A1 HK 1112718A1
Authority
HK
Hong Kong
Prior art keywords
aqueous ophthalmic
ophthalmic suspension
crystalline rebamipide
rebamipide
crystalline
Prior art date
Application number
HK08101628.0A
Other languages
English (en)
Inventor
Takakuni Matsuda
Shogo Hiraoka
Yuso Tomohira
Shinichi Ishikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1112718A1 publication Critical patent/HK1112718A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK08101628.0A 2004-11-15 2008-02-14 Aqueous ophthalmic suspension of crystalline rebamipide HK1112718A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004330140 2004-11-15
PCT/JP2005/021178 WO2006052018A1 (en) 2004-11-15 2005-11-11 Aqueous ophthalmic suspension of crystalline rebamipide

Publications (1)

Publication Number Publication Date
HK1112718A1 true HK1112718A1 (en) 2008-09-12

Family

ID=36336674

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08101628.0A HK1112718A1 (en) 2004-11-15 2008-02-14 Aqueous ophthalmic suspension of crystalline rebamipide

Country Status (16)

Country Link
US (2) US9211254B2 (es)
EP (1) EP1812000A4 (es)
JP (3) JP4934587B2 (es)
KR (1) KR101271959B1 (es)
CN (1) CN100594901C (es)
AR (2) AR052779A1 (es)
AU (1) AU2005302908B2 (es)
BR (1) BRPI0518928A2 (es)
CA (1) CA2584017C (es)
HK (1) HK1112718A1 (es)
MX (1) MX2007005782A (es)
MY (1) MY152867A (es)
RU (1) RU2398585C2 (es)
SG (1) SG156692A1 (es)
TW (1) TWI363626B (es)
WO (1) WO2006052018A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
RU2538694C2 (ru) * 2008-06-19 2015-01-10 Оцука Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
AR085527A1 (es) 2011-03-24 2013-10-09 Otsuka Pharma Co Ltd Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
TW201322982A (zh) * 2011-11-01 2013-06-16 Otsuka Pharma Co Ltd 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑
SA113340675B1 (ar) * 2012-06-26 2015-08-16 استيش. كو.، ليمتد أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
EP2996673A1 (en) * 2013-05-16 2016-03-23 Universiteit Antwerpen Thermolabile drug release formulation
TWI697337B (zh) 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN104586762A (zh) * 2014-04-11 2015-05-06 广州仁恒医药科技有限公司 含有瑞巴派特的药物组合物及其制备方法
JP6854587B2 (ja) * 2015-04-17 2021-04-07 ロート製薬株式会社 医薬製剤
KR101718733B1 (ko) * 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
KR20170039347A (ko) 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
KR102307958B1 (ko) 2015-10-01 2021-10-05 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
JP6732441B2 (ja) * 2015-12-11 2020-07-29 ロート製薬株式会社 局所粘膜適用水性組成物
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR102615076B1 (ko) * 2021-07-14 2023-12-19 대우제약 주식회사 안정한 레바미피드 점안제의 대용량 제조 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50121414A (es) 1974-02-18 1975-09-23
JPS55139319A (en) 1979-04-13 1980-10-31 Furointo Sangyo Kk Activation of drug soluble in alkali and acid
KR0181973B1 (ko) 1991-03-27 1999-05-01 오가타 가즈미 수성 현탁액제의 제조 방법
JP2808378B2 (ja) * 1991-03-27 1998-10-08 武田薬品工業株式会社 水性懸濁液剤の製造法
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
AR004214A1 (es) 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
JPH09301855A (ja) * 1996-05-13 1997-11-25 Fuairudo Kk 健康用部材
US6274634B1 (en) 1997-05-14 2001-08-14 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
GB9810859D0 (en) * 1998-05-20 1998-07-22 Zeneca Ltd Crystallisation process
MXPA03011538A (es) * 2001-06-14 2004-03-09 Otsuka Pharma Co Ltd Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.

Also Published As

Publication number Publication date
CN101056636A (zh) 2007-10-17
BRPI0518928A2 (pt) 2008-12-16
RU2398585C2 (ru) 2010-09-10
KR101271959B1 (ko) 2013-06-10
JP2012092139A (ja) 2012-05-17
CN100594901C (zh) 2010-03-24
JP4934587B2 (ja) 2012-05-16
TW200621252A (en) 2006-07-01
TWI363626B (en) 2012-05-11
AU2005302908A1 (en) 2006-05-18
RU2007122392A (ru) 2008-12-20
EP1812000A1 (en) 2007-08-01
JP2014077012A (ja) 2014-05-01
AU2005302908B2 (en) 2011-03-31
MY152867A (en) 2014-11-28
SG156692A1 (en) 2009-11-26
CA2584017C (en) 2013-08-27
AR108955A2 (es) 2018-10-10
US9211254B2 (en) 2015-12-15
US20070287729A1 (en) 2007-12-13
KR20070092965A (ko) 2007-09-14
AR052779A1 (es) 2007-04-04
CA2584017A1 (en) 2006-05-18
US9533052B2 (en) 2017-01-03
WO2006052018A1 (en) 2006-05-18
US20160101183A1 (en) 2016-04-14
JP2008519759A (ja) 2008-06-12
MX2007005782A (es) 2007-07-19
EP1812000A4 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
HK1112718A1 (en) Aqueous ophthalmic suspension of crystalline rebamipide
HRP20180629T1 (hr) Vodene suspenzije tmc278
AP2038A (en) Treatment of aqueous suspensions
PT1802579E (pt) Derivados da 3-arilaminopiridina
AP2716A (en) Treatment of aqueous suspensions
FR2883839B1 (fr) Suspension arriere de turboreacteur
IL185498A0 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
EP1838906A4 (en) PREPARATION OF SUSPENSIONS
IL176141A0 (en) Crystalline forms of valacyclovir hydrochloride
HK1098486A1 (en) Aqueous suspensions of ciclesonide for nebulisation
IL183185A0 (en) Process of making crystalline aripiprazole
IL185757A0 (en) Methods of decreasing calcifcation
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
EP1912499A4 (en) PREPARATION OF MONTELUKAST
HK1093399A1 (en) Aqueous suspension preparation of bactericide for folieage application
HK1148527A1 (en) Amine salt of carbostyril derivative
EP1932247A4 (en) ADAPTIVE AREA OF INFLUENCE FILTER
AU2003232719A1 (en) Novel crystalline forms of valacyclovir hydrochloride
EP1831171A4 (en) PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
ZA200508283B (en) Aqueous agricultural-chemical suspension composition
ZA200706292B (en) Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
IL177123A0 (en) Stable amorphous forms of montelukast sodium
AU2004905035A0 (en) Treatment of Ophthalmic Conditions
AU2004907326A0 (en) Preparation of Suspensions
AU2003230194A1 (en) Novel crystalline forms of gatifloxacin

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171111